Carregant...
Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions
Since the year 2000, tremendous progress has been made in the understanding of castration-resistant prostate cancer (crpc), a disease state now recognized to retain androgen receptor (ar)—dependency in most cases. That understanding led to the rational design of novel therapeutic agents targeting ho...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Multimed Inc.
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3553559/ https://ncbi.nlm.nih.gov/pubmed/23355790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.19.1281 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|